Rabies Vaccine Market Size & Share 2026-2035

Rabies Vaccine Market Size

The global rabies vaccine market was valued at USD 1.2 billion in 2025. The market is estimated to grow from USD 1.3 billion in 2026 to USD 1.9 billion by 2035, expanding at a CAGR of 4.5% during the forecast period, as per the latest report published by Global Market Insights Inc.

Growing awareness about rabies prevention, increasing number of animal bite cases, increasing use of post-exposure prophylaxis (PEP), and increased government efforts for rabies vaccinations in developing nations are some of the factors propelling the market growth. In addition, efforts towards eradicating rabies deaths and making vaccines more available in emerging economies are expected to drive market demand.

Rabies is a major public health concern, particularly in Asia and Africa. According to the World Health Organization, rabies is responsible for nearly 59,000 human deaths annually across more than 150 countries, with approximately 95% of cases occurring in Africa and Asia. The WHO further states that nearly 99% of human rabies transmissions are caused by infected dogs, with approximately half of the cases attributable to children under 15 years of age.

Growing exposure to potentially rabid animals is also contributing to increased vaccine demand. According to the Centers for Disease Control and Prevention, around 100,000 Americans receive rabies post-exposure prophylaxis annually following suspected exposure to rabid animals. Further, according to the CDC Rabies Surveillance data, about 1.4 million Americans seek medical evaluation for potential rabies exposure every year. These rising exposure rates, combined with increasing public awareness and rapid treatment adoption, continue to support market expansion.

Rabies vaccines are biologic formulations designed to stimulate immunity against the rabies virus, a nearly always fatal viral infection once clinical symptoms appear. These vaccines are administered both as pre-exposure prophylaxis (PrEP) for high-risk populations such as veterinarians, laboratory personnel, and travellers, as well as post-exposure prophylaxis following animal bites or scratches.

The rabies vaccine market experienced steady expansion owing to rising government-supported immunization campaigns, growing investments in veterinary rabies control, and increasing healthcare expenditure in endemic regions. Countries including India, China, and several African nations have intensified rabies prevention initiatives through mass dog vaccination campaigns and expanded access to human rabies vaccines. In parallel, international organizations including the WHO, the Food and Agriculture Organization, and the World Organization for Animal Health are actively supporting the global “Zero by 30” initiative, which aims to eliminate dog-mediated human rabies deaths by 2030.

Rabies Vaccine Market Trends

The rabies vaccine industry is experiencing steady growth owing to the growing burden of rabies exposure, increased awareness about preventative vaccination, and increasing government efforts toward rabies elimination programs worldwide.

• In the U.S., around 4,000 animal rabies cases are reported each year, with more than 90% occurring in wildlife like bats, raccoons, skunks, and foxes. Similarly, the annual estimated number of dog bites in India is 17.4 million, leading to estimated 18 000–20 000 cases of human rabies per year.
• Such a high burden of animal bite exposures and rabies-related mortality continues to significantly increase the demand for rabies vaccines and post-exposure prophylaxis therapies globally.
• Further, according to the World Health Organization, over 29 million people worldwide receive human rabies. The increasing number of animal bite exposures and growing awareness regarding immediate post-bite vaccination continue to drive substantial demand for rabies vaccines globally.
• The market is also benefiting from rising government-supported vaccination and rabies elimination programs. For example, India, which accounts for a significant share of global rabies deaths, has intensified its National Rabies Control Programme (NRCP) to improve access to anti-rabies vaccines and strengthen dog vaccination campaigns.
• Further, increasing utilization of rabies vaccines for post-exposure prophylaxis (PEP) is significantly contributing to market growth. Rising awareness regarding the importance of immediate vaccination after animal bites and scratches is supporting consistent vaccine demand across both developed and developing regions.
• Moreover, expansion in healthcare infrastructure and improvement in the distribution of biologics in developing nations are driving market growth positively. The growing expenditure on healthcare, increased availability of vaccines at rural health care centers, development of cold chain infrastructure in countries such as India, China, Indonesia, Bangladesh, and Brazil, are aiding the widespread use of vaccines.
• Also, reimbursements by government bodies and global organizations to prevent neglected tropical diseases are further driving the market growth.

Rabies Vaccine Market Analysis

Based on the product type, the rabies vaccine market is segmented into Baby Hamster Kidney (BHK), purified chick embryo cell rabies vaccine, Vero cell rabies vaccine, and other product types. The Baby Hamster Kidney (BHK) segment dominated the market in 2025 and accounted for USD 492 million.

• The Baby Hamster Kidney (BHK) segment holds a significant share in the rabies vaccine industry because it is commonly used in the manufacturing of viral vaccines and has high potential for the large-scale production of cell culture.
• The BHK cells are widely used for the production of inactivated rabies vaccine owing to their high viral yield, fast growth characteristics and the ability to support efficient rabies virus propagation under controlled bioprocessing conditions.
• The increasing preference for cell culture-based vaccines over traditional nerve tissue-derived vaccines has further strengthened the adoption of BHK cell technology in rabies vaccine manufacturing.
• The Vero cell rabies vaccine segment is expected to witness strong growth at a CAGR of 5.3%, owing to its superior safety profile, high immunogenicity, and increasing adoption in both pre-exposure and post-exposure prophylaxis programs globally.
• In addition, cost-effectiveness and suitability for large-scale commercial production are also driving the growth of the segment.
• Purified chick embryo cell rabies vaccine held a market share 23.1% in 2025 because of its proven efficacy, good safety profile, and broad use in post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP).
• Further, growing awareness of timely immunization against rabies and increasing accessibility of vaccination in endemic areas are boosting the demand for vaccines based on PCECV.

Based on the type, the rabies vaccine market is segmented into human and veterinary. The human segment held a market share of 68.8% in 2025.

• The human vaccines segment accounted for the largest share of the rabies vaccine industry owing to the high global burden of human rabies exposures and increasing demand for post-exposure prophylaxis (PEP) following animal bites.
• Segment leadership continues to be supported by increasing awareness of immediate rabies treatment, expanding government-supported immunization programs and increasing availability of modern cell culture-based vaccines.
• Additionally, the human vaccines segment is also gaining traction globally due to the increasing healthcare expenditure, improving access to vaccines in endemic regions, and ongoing public health initiatives to eliminate human rabies deaths.
• The veterinary rabies vaccines segment is growing steadily at a CAGR of 3.9%, due to the increasing focus on animal health management and the increasing mass dog vaccination programs for controlling rabies transmission.
• Demand for veterinary rabies vaccines worldwide is continuing to be supported by growing government and international initiatives to eradicate dog-mediated human rabies deaths, rising pet adoption, and measures to protect livestock.

Based on the application, the rabies vaccine market is segmented into pre-exposure prophylaxis and post exposure prophylaxis. The post exposure prophylaxis segment dominated the market in 2025 and is anticipated to grow at a CAGR of 4.1% between 2026 - 2035.

• The segment’s dominance is primarily owing to the high prevalence of animal bite incidents across the globe, rising awareness about prompt treatment for rabies, and strong government recommendations for timely administration of rabies vaccines after suspected exposure.
• Moreover, growing public health initiatives and access to emergency vaccination services in rabies-endemic countries support segment growth.
• On the other hand, the pre-exposure prophylaxis (PrEP) segment is anticipated to witness growth at a CAGR of 5.5%, owing to the rising vaccination in high-risk populations, including veterinarians, laboratory personnel, animal handlers, and international travelers.
• Growing awareness of preventive rabies immunization and growing recommendations for occupational vaccination in endemic regions are other factors boosting demand for pre-exposure rabies vaccines.

Based on the distribution channel, the rabies vaccine market is segmented into hospital pharmacies, online pharmacies, and retail pharmacy. The hospital pharmacies segment dominated the market in 2025 and is anticipated to reach USD 1.1 billion by 2035.

• The hospital pharmacies segment dominated the rabies vaccine industry owing to the high administration of post-exposure prophylaxis (PEP) vaccines in emergency and inpatient settings following animal bite incidents.
• Hospitals remain the primary point of care for rabies management due to the availability of trained healthcare professionals and complete vaccination facilities.
• In addition, increasing hospitalization rates and strong government supply programs for anti-rabies biologics continue to support segment dominance.
• The retail pharmacies segment held a market share of 26.7% in 2025 and is expected to witness strong growth due to increasing accessibility of rabies vaccines through community pharmacy networks and rising demand for rapid post-exposure treatment.
• Expanding number of retail pharmacies and improving availability of biologics in urban and semi-urban regions are further supporting segment growth.
• Further, the online pharmacies segment is witnessing growing adoption due to increasing digital healthcare penetration and rising consumer preference for convenient medicine purchasing platforms.

North America Rabies Vaccine Market

North America dominated the global rabies vaccines market with a market share of 39.3% in 2025.

• North America, particularly the U.S., holds a strong position in the rabies vaccine industry owing to advanced healthcare infrastructure, high awareness regarding rabies prevention, and widespread access to post-exposure prophylaxis (PEP) services.
• The U.S. rabies vaccine market size reached USD 419.7 million in 2025, growing from USD 401.8 million in 2024.
• The U.S. rabies vaccine industry continues to witness stable growth due to increasing animal exposure incidents and strong public health surveillance systems.
• For instance, as per the National Foundation for Infectious Diseases, about 5,000 animal rabies cases are reported in the U.S. each year, with more than 90% of the cases occurring in wildlife. About 10% of animal rabies cases in the U.S. occur in domestic animals such as dogs and cats.
• Wildlife-associated rabies remains a major public health concern in the region. The CDC reports that bats account for nearly 70% of human rabies cases acquired in the U.S., while raccoons, skunks, and foxes continue to represent major rabies reservoirs.
• In addition, high healthcare spending, strong vaccine reimbursement frameworks, and the presence of major vaccine manufacturers continue to support regional market dominance.
• Growing adoption of preventive vaccination among veterinarians, animal control workers, and travelers is further contributing to market expansion across North America.

Europe Rabies Vaccine Market

Europe market accounted for a considerable revenue of USD 223.2 million in 2025 and is anticipated to witness steady growth during the forecast period.

• Market growth is primarily supported by increasing awareness regarding zoonotic disease prevention, strong public healthcare systems, and rising demand for preventive vaccination among travelers and high-risk occupational groups.
• Several European countries maintain strict animal vaccination and rabies surveillance programs, which continue to support stable vaccine procurement activities.
• In addition, increasing international travel to rabies-endemic regions is driving demand for pre-exposure prophylaxis vaccines across Europe. Further, high adoption of pre-exposure prophylaxis vaccines among high-risk groups further drives the demand.
• Rabies pre-exposure prophylaxis (PrEP) coverage in Europe is highly heterogeneous, with an estimated 70% to 80% of eligible travelers failing to get vaccinated. However, for high-risk occupational groups like veterinarians and zookeepers, coverage generally exceeds 60%.
• Furthermore, the region also benefits from strong government support for public immunization infrastructure and widespread access to veterinary vaccination programs is expected to support long-term market growth across the region.

Asia Pacific Rabies Vaccine Market

The Asia Pacific market is anticipated to grow at the highest CAGR during the forecast period.

• The growth is primarily attributed to the high burden of rabies cases, large stray dog populations, rapidly expanding healthcare infrastructure, and increasing government-led vaccination programs across countries such as India, China, Indonesia, and Bangladesh.
• According to the World Health Organization, Asia accounts for the majority of global rabies deaths, making the region the largest consumer of rabies vaccines worldwide.
• India represents one of the largest regional markets due to the high incidence of animal bites. According to WHO, India accounts for 36% of the global deaths due to rabies and 65% of the deaths due to rabies in the Southeast Asia region. India, being highly endemic for rabies, has the largest number of animal bites in the World. Nationwide, there are an estimated 1.7 crore animal bite cases reported every year, with stray dogs responsible for over 96% of rabies transmissions.
• China continues to strengthen its rabies prevention infrastructure through expanded dog vaccination campaigns and improved access to post-exposure treatment services. In addition, increasing healthcare expenditure, expanding biologics manufacturing capabilities, and rising public awareness regarding rabies prevention continue to support strong market growth across Asia Pacific.

Latin America Rabies Vaccine Market

The Latin America market is experiencing steady growth over the analysis timeframe.

• Countries such as Brazil and Mexico are increasingly investing in zoonotic disease prevention programs, public immunization infrastructure, and mass animal vaccination initiatives, supporting growing demand for rabies vaccines.
• Brazil remains one of the key regional markets owing to its large population base and active rabies surveillance programs. According to the Pan American Health Organization (PAHO), Latin American countries have made significant progress in reducing dog-mediated human rabies cases through expanded vaccination campaigns and improved access to post-exposure prophylaxis.
• In addition, increasing pet ownership, improving healthcare access, and expanding government-supported vaccination programs are supporting broader adoption of rabies biologics across the region.

Middle East & Africa Rabies Vaccine Market

The Middle East & Africa market is witnessing notable growth over the analysis timeframe.

• The market growth is primarily supported by the high burden of rabies exposures in several African countries, increasing dog vaccination campaigns, and improving access to post-exposure prophylaxis services.
• According to the World Health Organization, Africa accounts for a substantial share of global rabies mortality, with limited healthcare access and low vaccination coverage continuing to impact disease control efforts in several regions. For instance, it is estimated that 60% of rabies human deaths occur in Africa.
• Governments and international health organizations are increasingly investing in rabies elimination programs, public awareness campaigns, and vaccine procurement initiatives to reduce rabies-related deaths across endemic countries. For instance, the Pan-African Strategy for the Elimination of Rabies in Africa (PASERA) 2026–2030 provides a coordinated, African-led One Health framework to eliminate dog-mediated rabies as a public health threat by 2030.
• Furthermore, expansion of veterinary vaccination programs and strengthening of healthcare infrastructure are expected to further accelerate rabies vaccine adoption across the MEA region.

Rabies Vaccine Market Share

The rabies vaccine industry is moderately consolidated, with competition driven by the presence of established vaccine manufacturers, regional biologics companies, and government-supported vaccine suppliers. Leading companies including Sanofi, Zoetis, Merck & Co., Bharat Biotech, and Liaoning Cheng maintain strong market positions with a combined market share of ~48%. The players maintain their leading positions through extensive rabies vaccine portfolios, large-scale manufacturing capabilities, and broad distribution networks across public and private healthcare sectors.

Market participants primarily compete based on vaccine pricing, production capacity, regulatory approvals, geographic reach, and long-term government procurement contracts for rabies immunization programs. In addition, increasing global efforts to eliminate dog-mediated human rabies deaths are encouraging manufacturers to strengthen partnerships with governments, international health organizations, and public immunization agencies. Rising demand for affordable rabies vaccines in Asia and Africa has further accelerated investments in cost-efficient manufacturing technologies, cold-chain distribution infrastructure, and next-generation biologic therapies.

Rabies Vaccine Market Companies

A few of the prominent players operating in the rabies vaccine industry include:

• AIM Vaccine
• Bharat Biotech
• Boehringer Ingelheim
• Bavarian Nordic
• Biogénesis Bagó
• Chengdu Institute of Biological Products
• Cadila Pharmaceuticals
• Elanco Animal Health
• Indian Immunologicals Ltd.
• Liaoning Cheng Da Co., Ltd.
• Merck & Co.
• Sanofi
• Virbac
• Zoetis
• Zydus Lifesciences

• Sanofi

Sanofi is a leading player in the rabies vaccines market with a strong global presence in human rabies prophylaxis through its widely used Verorab and Imovax rabies vaccines. The company benefits from extensive vaccine manufacturing capabilities, broad international distribution networks, and strong participation in government and public health immunization programs, particularly across Asia, Africa, and Europe.

• Zoetis

Zoetis is a major player in the veterinary rabies vaccines market, supported by its broad companion animal and livestock vaccine portfolio. The company benefits from strong global veterinary distribution networks and increasing demand for preventive animal vaccination programs aimed at controlling rabies transmission.

Rabies Vaccine Industry News

• In April 2026, researchers from the University of Oxford announced positive clinical findings for a new single-dose rabies vaccine candidate, ChAdOx2 RabG, demonstrating stronger and longer-lasting immune responses compared with currently available rabies vaccines in both adults and children. The development is expected to support future advancements in affordable and simplified rabies immunization programs, particularly across low-resource regions.
• In April 2024, Sanofi announced the launch of Verorab (Sanofi inactivated rabies vaccine) in UK. Verorab is an inactivated rabies vaccine indicated for pre-exposure and post-exposure prophylaxis of rabies in all age groups. This helped the company expand its sales in Europe.
• In April 2022, Cadila Pharmaceuticals launched a three-dose recombinant nanoparticle-based G protein rabies vaccine in Ahmedabad. This is a three-dose regimen to be given over a period of one week (on day 0, day three, and day seven) after exposure to the virus. It is the first in a long list of existing rabies vaccines that require five doses. This helped the company expand its product offerings.

The rabies vaccine market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Baby Hamster Kidney (BHK)
• Purified chick embryo cell rabies vaccine
• Vero cell rabies vaccine
• Other product types

Market, By Type

• Human
• Veterinary

Market, By Application

• Pre exposure prophylaxis
• Post exposure prophylaxis

Market, By Distribution Channel

• Hospital pharmacies
• Online pharmacies
• Retail pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE